These findings highlight the potential therapeutic benefit of simultaneously targeting the POSTN-NOTCH1 axis in both cancer cells and the tumor microenvironment for effective suppression of SCLC tumor growth in vivo. This evidence concerns the gene POSTN and neoplasm.